Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Share-based Compensation for 18 consecutive years, with $43.0 million the latest figure, recorded in Q1 2026.

• Quarterly Share-based Compensation rose 26.47% year-over-year to $43.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.0 million (up 28.68% YoY) and the FY2025 annual result came in at $157.0 million, up 27.64% from the prior year.
• Share-based Compensation eased to $43.0 million in Q1 2026 per TEVA's latest filing, from $51.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for TEVA reached as high as $51.0 million in Q4 2025 and fell as low as $24.0 million in Q1 2022.
• A 5-year average of $33.5 million and a median of $32.0 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation dropped 23.08% — and 2025, when it surged 50.0%.
• Year by year, Share-based Compensation stood at $36.0 million in 2022, then declined by 22.22% to $28.0 million in 2023, then climbed by 21.43% to $34.0 million in 2024, then jumped by 50.0% to $51.0 million in 2025, then dropped by 15.69% to $43.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $43.0 million, $51.0 million, and $34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.